Roche received marketing authorization from the European Commission for Ronapreve (casirivimab and imdevimab), to treat COVID-19 in adults and adolescents (12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of their disease becoming severe, and for preventing COVID-19 in people aged 12 years and older pre- or post-exposure prophylaxis.   The decision is based on the EMA’s CHMP’s review of positive data from the REGN-COV 2067...